Abstract
Background
The genetics of inflammatory bowel diseases (IBD) has brought new insight into the spectrum of disease phenotypes that are collectively labeled as either Crohn’s disease or ulcerative colitis. In concert with the pharmacogenomics of drug therapy, it has led clinicians to develop the notion of a more tailored approach to therapy.
Data sources
Articles were searched from PubMed (1995–2010) with key words “inflammatory bowel diseases”, “Genetics”, “pharmacogenomics”.
Results
Among all the putative susceptibility loci, the NOD2 gene has been the most studied and linked to an aggressive form of stricturing and perforating disease of the ileum. Other potential gene polymorphisms, including those encoding for the interleukin-23 receptor, have lent themselves to the recent development of potential novel immunosuppressive therapies. While the linkage of a number of autophagy genes with either Crohn’s disease or ulcerative colitis has provided insight into the innate adaptive immune pathway’s response to commensual intestinal bacteria. Pharmacogenetic polymorphisms of azathioprine metabolism have been shown to predict toxicity to anti-metabolite therapy. Patients with absent thiopurine methyl transferase enzyme activity are at risk for irreversible bone marrow suppression, and are not considered good candidates for either 6-mercaptopurine (6-MP) or azathioprine therapy.
Conclusions
Ultimately, the correlation between these genotypes and clinical phenotype of disease will inevitably lead to an improved understanding of disease natural history and a more tailored approach to therapy. Although there is ongoing debate as to whether these inherent differences in enzyme activity can predict responsiveness to anti-metabolite therapy, some gastroenterologists do find value in 6-MP metabolite testing as a means of monitoring patient compliance and tailoring the dose of anti-metabolite therapy based on a perceived therapeutic window. In the future, patients with IBD will ultimately be categorized based on their genomic imprint to allow for a better delineation of disease phenotype. Furthermore, the application pharmacogenomics of drug therapy into clinical practice will be pivotal in maximizing treatment response while avoiding untoward side-effects.
Similar content being viewed by others
References
Mendeloff AI, Calkins BM. The epidemiology of idiopathic inflammatory bowel disease. In: Kirsner JB, Shorter RG, eds. Inflammatory Bowel Disease. Philadelphia: Lea & Febiger, 1988: 3–34.
Mendeloff AI. The epidemiology of Inflammatory Bowel Disease. Clin Gastroenterol 1980;9:258.
Satsangi J, Jewell DP, Rosenberg WM, Bell JI. Genetics of inflammatory bowel disease. Gut 1994;35:696–700.
Yang H, McElree C, Roth MP, Shanahan F, Targan SR, Rotter JI. Familial empirical risks for inflammatory bowel disease: differences between Jews and non-Jews. Gut 1993;34:517–524.
Thompson NP, Driscoll R, Pounder RE, Wakefield AJ. Genetics versus environment in inflammatory bowel disease: results of a British twin study. BMJ 1996;312:95–96.
Mcbride JA, King MJ, Baikie AG, Crean GP, Sircus W. Ankylosing spondylitis and chronic inflammatory bowel diseases of the intestines. Br Med J 1963;2:483–486.
Price WH. A high incidence of chronic inflammatory bowel disease in patients with Turner’s syndrome. J Med Genet 1979;16:263–266.
Bennett RA, Rubin PH, Present DH. Frequency of inflammatory bowel disease in offspring of couples both presenting with inflammatory bowel disease. Gastroenterology 1991;100:1638–1643.
Hugot JP, Laurent-Puig P, Gower-Rousseau C, Olson JM, Lee JC, Beaugerie L, et al. Mapping of a susceptibility locus for Crohn’s disease on chromosome 16. Nature 1996;379:821–823.
Ohmen JD, Yang HY, Yamamoto KK, Zhao HY, Ma Y, Bentley LG, et al. Susceptibility locus for inflammatory bowel disease on chromosome 16 has a role in Crohn’s disease, but not in ulcerative colitis. Hum Mol Genet 1996;5:1679–1683.
Cho JH, Fu Y, Kirschner B. Hanauer SB. Confirmation of susceptibility locus IBD 1 for Crohn’s disease on chromosome 16. Gastroenterology 1997;112:A948.
Cavanaugh JA, Callen DF, Wilson SR, Stanford PM, Sraml ME, Gorska M, et al. Analysis of Australian Crohn’s disease pedigrees refines the localization for susceptibility to inflammatory bowel disease on chromosome 16. Ann Hum Genet 1998;62:291–298.
Hampe J, Wienker T, Nurnberg P, Schreiber S. Mapping genes for polygenic disorders: considerations for study design in the complex trait in inflammatory bowel disease. Hum Hered 2000;50:91–101.
Hofmeister A, Neibergs HL, Pokorny RM, Galandiuk S. The natural resistance-associated macrophage protein gene is associated with Crohn’s disease. Surgery 1997;122:173–178.
Brant SR, Panhuysen CI, Bailey-Wilson JE. Rohal PM, Lee S, Mann J, et al. Linkage heterogeneity for the IBD 1 locus in Crohn’s disease pedigrees by disease onset and severity. Gastroenterology 2000;119:1483–1490.
Duerr RH, Neigut DA. Molecularly defined HLA-DR2 alleles in ulcerative colitis and an antineutrophil cytoplasmic antibody-positive subgroup. Gastroenterology 1995;108:423–427.
Curran ME, Lau KF, Hampe J, Schreiber S, Bridger S, Macpherson AJ, et al. Genetic analysis of inflammatory bowel disease in a large European cohort supports linkage to chromosome 12 and 16. Gastroenterology 1998;115:1066–1071.
Hampe J, Grebe J, Nikolaus S, Solberg C, Croucher PJ, Mascheretti S, et al. Association of NOD2 (CARD 15) genotype with clinical course of Crohn’s disease: a cohort study. Lancet 2002;359:1661–1665.
Lesage S, Zouali H, Cézard JP, the EPWG-IBD group, Colombel JF, the EPIMAD group, et al. CARD15/NOD2 mutational analysis and genotype-phenotype correlation in 612 patients with inflammatory bowel disease. Am J Hum Genet 2002;70:845–857.
Blumberg RS, Strober W. Prospects for research in inflammatory bowel disease. JAMA 2001;285:643–647.
Kugathasan S, Collins N, Maresso K, Hoffmann RG, Stephens M, Werlin SL, et al. CARD15 gene mutations and risk for early surgery in pediatric-onset Crohn’s disease. Clin Gastroenterol Hepatol 2004;2:1003–1009.
Chamaillard M, Iacob R, Desreumaux P, Colombel JF. Advances and perspectives in the genetics of inflammatory bowel diseases. Clin Gastroenterol Hepatol 2006;4:143–151.
Kobayashi KS, Chamaillard M, Ogura Y, Henegariu O, Inohara N, Nuñez G, et al. Nod2-dependent regulation of innate and adaptive immunity in the intestinal tract. Science 2005;307:731–734.
Rioux JD, Silverberg MS, Daly MJ, Steinhart AH, McLeod RS, Griffiths AM, et al. Genomewide search in Canadian families with inflammatory bowel disease reveals two novel susceptibility loci. Am J Hum Genet 2000;66:1863–1870.
Friedrichs F, Brescianini S, Annese V, Latiano A, Berger K, Kugathasan S, et al. Evidence of transmission ratio distortion of DLG5 R30Q variant in general and implication of an association with Crohn disease in men. Hum Genet 2006;119:305–311.
Török HP, Glas J, Tonenchi L, Mussack T, Folwaczny C. Polymorphisms of the lipopolysaccharide-signaling complex in inflammatory bowel disease: association of a mutation in the Toll-like receptor 4 gene with ulcerative colitis. Clin Immunol 2004;112:85–91.
Cario E, Podolsky DK. Differential alteration in intestinal epithelial cell expression of toll-like receptor 3 (TLR3) and TLR4 in inflammatory bowel disease. Infect Immun 2000;68:7010–7017.
Franchimont D, Vermeire S, El Housni H, Pierik M, Van Steen K, Gustot T, et al. Deficient host-bacteria interactions in inflammatory bowel disease? The toll-like receptor (TLR)-4 Asp299gly polymorphism is associated with Crohn’s disease and ulcerative colitis. Gut 2004;53:987–992.
Török HP, Glas J, Tonenchi L, Bruennler G, Folwaczny M, Folwaczny C. Crohn’s disease is associated with a toll-like receptor-9 polymorphism. Gastroenterology 2004;127:365–366.
Duerr RH, Taylor KD, Brant SR, Rioux JD, Silverberg MS, Daly MJ, et al. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 2006;314:1461–1463.
Hampe J, Franke A, Rosenstiel P, Till A, Teuber M, Huse K, et al. A genome-wide association scan of nonsynonymous SNPs identifies a susceptibility variant for Crohn disease in ATG16L1. Nat Genet 2007;39:207–211.
Bonen DK, Cho JH. The genetics of inflammatory bowel disease. Gastroenterology 2003;124:521–536.
Lazaridis KN, Petersen GM. Genomics, genetic epidemiology, and genomic medicine. Clin Gastroenterol Hepatol 2005;3:320–328.
Parkes M, Barrett JC, Prescott NJ, Tremelling M, Anderson CA, Fisher SA, et al. Sequence variants in the autophagy gene IRGM and multiple other replicating loci contribute to Crohn’s disease susceptibility. Nat Genet 2007;39:830–832.
Collazo CM, Yap GS, Sempowski GD, Lusby KC, Tessarollo L, Woude GF, et al. Inactivation of LRG-47 and IRG-47 reveals a family of interferon gamma-inducible genes with essential, pathogen-specific roles in resistance to infection. J Exp Med 2001;194:181–188.
Shanahan F, O’Mahony J. The mycobacteria story in Crohn’s disease. Am J Gastroenterol 2005;100:1537–1538.
Gurbindo C, Seidman EG. Gastrointestinal manifestations of primary immunodeficiency disorders. In: Walker WA, Durie PR, Hamilton JR, Walker-Smith JA, Watkins B, eds. Pediatric Gastrointestinal Disease Pathophysiology, Diagnosis, Management, 2nd ed. St. Louis: Mosby CV, 1996: 585–605.
D’Agata ID, Vanounou T, Seidman E. Mesalamine in pediatric inflammatory bowel disease: a 10-year experience. Inflamm Bowel Dis 1996;2:229–235.
Shivananda S, Peña AS, Nap M, Weterman IT, Mayberry JF, Ruitenberg EJ, et al. Epidemiology of Crohn’s disease in Regio Leiden, The Netherlands. A population study from 1979 to 1983. Gastroenterology 1987;93:966–974.
Seidman EG. Inflammatory Bowel disease. In: Roy CC, Silverman A, Alagille A, eds. Clinical Pediatric Gastroenterology, 4th ed. Mosby: Philadelphia, 1993.
Ekbom A, Adami HO, Helmick CG, Jonzon A, Zack MM. Perinatal risk factors for inflammatory bowel disease: a casecontrol study. Am J Epidemiol 1990;132:1111–1119.
Wakefield AJ, Ekbom A, Dhillon AP, Pittilo RM, Pounder RE. Crohn’s disease: pathogenesis and persistent measles virus infection. Gastroenterology 1995;108:911–916.
Ekbom A, Wakefield AJ, Zack M, Adami HO. Perinatal measles infection and subsequent Crohn’s disease. Lancet 1994;344:508–510.
Wakefield AJ, Pittilo RM, Sim R, Cosby SL, Stephenson JR, Dhillon AP, et al. Evidence of persistent measles virus infection in Crohn’s disease. J Med Virol 1993;39:345–353.
Lewin J, Dhillon AP, Sim R, Mazure G, Pounder RE, Wakefield AJ. Persistent measles virus infection of the intestine: confirmation by immunogold electron microscopy. Gut 1995;36:564–569.
Ekbom A, Wakefield AJ, Zack M, Adami HO. Perinatal measles infection and subsequent Crohn’s disease. Lancet 1994;344:508–510.
Lennard L. The clinical pharmacology of 6-mercaptopurine. Eur J Clin Pharmacol 1992;43:329–339.
Elion GB. The George Hitchings and Gertrude Elion Lecture. The pharmacology of azathioprine. Ann N Y Acad Sci 1993; 685:401–407.
Van Os EC, Zins BJ, Sandborn WJ, Mays DC, Tremaine WJ, Mahoney DW, et al. Azathioprine pharmacokinetics after intravenous, oral, delayed release oral and rectal foam administration. Gut 1996;39:63–68.
Lennard L, Lilleyman JS. Variable mercaptopurine metabolism and treatment outcome in childhood lymphoblastic leukemia. J Clin Oncol 1989;7:1816–1823.
Evans WE, Horner M, Chu YQ, Kalwinsky D, Roberts WM. Altered mercaptopurine metabolism, toxic effects, and dosage requirement in a thiopurine methyltransferase-deficient child with acute lymphocytic leukemia. J Pediatr 1991;119:985–989.
Cuffari C, Théorêt Y, Latour S, Seidman G. 6-Mercaptopurine metabolism in Crohn’s disease: correlation with efficacy and toxicity. Gut 1996;39:401–406.
Dubinsky MC, Lamothe S, Yang HY, Targan SR, Sinnett D, Théorêt Y, et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 2000;118:705–713.
Stevens T, Achkar JP, Easley K, Brzezinski A, Lashner B. Azathioprine formulation optimizes metabolite profile in inflammatory bowel disease. Aliment Pharmacol Ther 2004;20:601–606.
Cuffari C, Dassopoulos T, Turnbough L, Thompson RE, Bayless TM. Thiopurine methyltransferase activity influences clinical response to azathioprine in inflammatory bowel disease. Clin Gastroenterol Hepatol 2004;2:410–417.
Cuffari C, Hunt S, Bayless T. Utilisation of erythrocyte 6-thioguanine metabolite levels to optimise azathioprine therapy in patients with inflammatory bowel disease. Gut 2001;48:642–646.
Present DH, Meltzer SJ, Krumholz MP, Wolke A, Korelitz BI. 6-Mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity. Ann Intern Med 1989;111:641–649.
Kirschner BS. Safety of azathioprine and 6-mercaptopurine in pediatric patients with inflammatory bowel disease. Gastroenterology 1998;115:813–821.
Black AJ, McLeod HL, Capell HA, Powrie RH, Matowe LK, Pritchard SC, et al. Thiopurine methyltransferase genotype predicts therapy-limiting severe toxicity from azathioprine. Ann Intern Med 1998;129:716–718.
Bo J, Schrøder H, Kristinsson J, Madsen B, Szumlanski C, Weinshilboum R, et al. Possible carcinogenic effect of 6-mercaptopurine on bone marrow stem cells: relation to thiopurine metabolism. Cancer 1999;86:1080–1086.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Cuffari, C. The genetics of inflammatory bowel disease: diagnostic and therapeutic implications. World J Pediatr 6, 203–209 (2010). https://doi.org/10.1007/s12519-010-0219-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12519-010-0219-7